Our Competitive Strengths

We believe that we possess a number of competitive strengths that position us to become a leading biopharmaceutical company focused on inflammatory and immune-related diseases as well as underserved retinal diseases, including:

  • Validated technology and drug development capabilities. EOM613 and predecessor formulations have been explored in several human studies and have been demonstrated to be safe over long periods of administration with potential efficacy in diseases such as rheumatoid arthritis. The present Phase 1/2a study in COVID-19 patients in Brazil is generating important information on cytokines and the effect of EOM613 treatment on the levels of these cytokines and the relevance to clinical effects. This information will increase the present information on EOM613’s Mechanism of Acton and the relevance to various therapeutic areas.

    EOM147 represents a different and safer mode of application (topical eye drops versus the present intraocular injection) of well accepted VEGF type treatments for Age Related Macular Degeneration (AMD).
  • Novel pipeline addressing large underserved markets. Our product candidates include novel clinical-stage compounds that have significant scientific rationale for effectiveness. By initially targeting large markets that have significant unmet medical needs, we believe that we can drive adoption of new products and improve our competitive position. For example, we believe that our novel immunomodulator lead asset, EOM613, a peptide nucleic-acid solution with dual mechanism of action (both anti-inflammatory and pro-inflammatory) will be a cost effective and novel therapeutic approach to aid millions in not only managing the symptoms of cancer cachexia and rheumatoid arthritis but in COVID-19 and other viral diseases. Moreover, the ease of administering EOM147 via an at-home eyedrop solution as opposed to a monthly intraocular injection at a certified opthalmologist, will ease the burden of millions of people suffering from Aged Related Macular degeneration, diabetic retinopathy and other debilitating retinal diseases. These diseases can have significant effects on patients’ quality of life and, and their employers, significant workplace-related costs and limitations.
  • Experienced leadership. Our leadership team possesses core capabilities in infectious diseases, cancer cachexia drug development, retinal diseases, drug development, chemistry, manufacturing and controls, and finance. In addition to our internal capabilities, we have also established a network of key opinion leaders, contract research organizations, contract manufacturing organizations and consultants. As a result, we believe we are well positioned to efficiently develop novel treatments for inflammatory and immune-related diseases.